Disposition of tradable shares by Chancellor Michael B of Lipella Pharmaceuticals subject to Rule 16b-3
| LIPO Stock | 2.63 0.21 8.68% |
About 72 percent of all Lipella Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Lipella Pharmaceuticals Common suggests that quite a few traders are confidant. Lipella Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Lipella Pharmaceuticals Common. Many technical investors use Lipella Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Lipella |
Filed transaction by Lipella Pharmaceuticals Officer Chief Medical Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Lipella Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Lipella Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Lipella Pharmaceuticals Fundamental Analysis
We analyze Lipella Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipella Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipella Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Lipella Pharmaceuticals is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Lipella Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lipella Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Lipella Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lipella Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Lipella Pharmaceuticals Related Equities
| FENC | Fennec Pharmaceuticals | 12.71 | ||||
| PTIX | Protagenic Therapeutics | 6.56 | ||||
| CELC | Celcuity LLC | 3.61 | ||||
| NGENF | NervGen Pharma | 3.35 | ||||
| SNTI | Senti Biosciences | 2.36 | ||||
| MNPR | Monopar Therapeutics | 1.98 | ||||
| ACRV | Acrivon Therapeutics, | 1.71 | ||||
| ICCC | ImmuCell | 0.82 | ||||
| INBX | Inhibrx | 0.72 | ||||
| ACOGF | Alpha Cognition | 0.52 | ||||
| TRGNF | Transgene | 0.00 | ||||
| ELYM | Eliem Therapeutics | 2.60 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.67 | ||||
| ELVN | Enliven Therapeutics | 3.42 | ||||
| ASCLF | Ascletis Pharma | 14.29 |
Check out Lipella Pharmaceuticals Hype Analysis, Lipella Pharmaceuticals Correlation and Lipella Pharmaceuticals Performance. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share 0.592 | Quarterly Revenue Growth 0.279 | Return On Assets (0.94) | Return On Equity (1.72) |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.